As a recognized service provider, Creative Biolabs’ highly skilled team can provide CellRapeutics™ first generation of CARs products to meet your specific needs. Creative Biolabs has built up a unique and unparalleled platform for producing a variety of CARs engineered immune cells, which can greatly help and accelerate your research progress.
Donald R. Shaffer, Penghui Zhou and Stephen Gottschalk. Foreign or Domestic CARs: Receptor Ligands as Antigen-Binding Domains. Med. Sci. 2014, 2(1), 23-36.
The design of the first generation CARs includes a scFv targeting tumor associated antigen (TAA), a space (hinge), a transmembrane region (TM) and an intracellular signaling domain. Clinical trials have shown that the first generation CAR-engrafted T cells are a very feasible concept in the treatment for some cancer patients. The application of CAR-engineered T cells have more advantages than the traditional T cell immunotherapy, which includes major histocompatibility complex (MHC)-independent antigen recognition in treating viral infection as well as cancer. Recent reports show that the first generation CAR modified T cells with anti-CD19 specificity has entered phrase I clinical trial for B cell malignances.
The scFv of the first generation CAR is derived from a monoclonal antibody specific to TAAs which is presented on tumor cell surface in various malignancies. Our seasoned scientists can provide a broad range of highly customized service for scFvs design to meet the growing requirements from our clients. An intracellular signaling domain is derived from the CD3ζ chain of the T cell receptor (TCR) complex, which can activate T cells. In addition to CD3ζ, FcεRIγ can also be used as an intracellular signaling domain.
Creative Biolabs offers you sophisticated strategy and the best-in-class CellRapeutics™ first generation CARs products, which can meet and exceed your original expectations.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE